Loading resource…

University of Gothenburg
The study investigates whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients experiencing acute coronary syndromes. It involves a randomized trial conducted in Sweden, where regions switched from ticagrelor to prasugrel as the default treatment. The primary endpoint includes a composite of death, myocardial infarction, or stroke over one year, assessed through national registries.
No account needed